(Q46025712)

18 December 2017

title

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. (English)

1 reference

18 December 2017

1 reference

4

1 reference

18 December 2017

Charles Erlichman

3

object named as

Charles Erlichman

1 reference

18 December 2017

author name string

Jan C Buckner

1

1 reference

18 December 2017

Bahram Forouzesh

2

1 reference

18 December 2017

Joseph P Boni

5

1 reference

18 December 2017

Gary Dukart

6

1 reference

18 December 2017

Anna Berkenblit

7

1 reference

18 December 2017

Eric K Rowinsky

8

1 reference

18 December 2017

publication date

5 May 2009

1 reference

18 December 2017

Investigational New Drugs

published in

1 reference

18 December 2017

volume

28

1 reference

18 December 2017

issue

3

1 reference

18 December 2017

page(s)

334-342

1 reference

18 December 2017

https://scigraph.springernature.com/pub.10.1007/s10637-009-9257-1

exact match

0 references

cites work

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

1 reference

12 December 2020

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

1 reference

12 December 2020

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

12 December 2020

Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.

1 reference

12 December 2020

CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling

1 reference

12 December 2020

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

1 reference

12 December 2020

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

1 reference

12 December 2020

Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.

1 reference

12 December 2020

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

1 reference

12 December 2020

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

1 reference

12 December 2020

The TOR pathway: a target for cancer therapy

1 reference

12 December 2020

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

1 reference

12 December 2020

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

1 reference

12 December 2020

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

12 December 2020

Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.

1 reference

12 December 2020

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

1 reference

12 December 2020

Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition

1 reference

12 December 2020

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

1 reference

12 December 2020

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

12 December 2020

TOR, a central controller of cell growth

1 reference

12 December 2020

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

1 reference

12 December 2020

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.

1 reference

12 December 2020

10.1007/S10637-009-9257-1

Identifiers

DOI

1 reference

18 December 2017

release_5enxye2tbrer5hifm2mfgvbtnu

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5enxye2tbrer5hifm2mfgvbtnu

24 November 2022

mapped directly with Wikidata item

PubMed ID

19415181

1 reference

18 December 2017